Primary hyperoxaluria type 1 (PH1) Program in Pharmaceutical Benefits Scheme (PBS) 012-25090506
This document outlines details of PBS-subsidised lumasiran for patients with primary hyperoxaluria type 1 (PH1).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.
Primary hyperoxaluria type 1 (PH1) quick reference
Table 1
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial PB389 form |
Written Electronic S85: lumasiran |
No |
OPA |
Must be treated by:
|
Yes - delayed assessment due to DPMQ (cost) |
|
Grandfather PB391 form |
Written Electronic S85: lumasiran |
No |
OPA |
Must be treated by:
|
Yes - delayed assessment due to DPMQ (cost) |
|
Continuing PB390 form |
Written Electronic S85: lumasiran |
No |
OPA |
Must be treated by:
|
Yes |
Enquiries about lumasiran (Oxlumo®) payments
Table 2
|
Step |
Action |
|
1 |
Transfer enquiries Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, option 4. |
|
2 |
Advise approved supplier Service Officers who receive a call about payments of lumasiran (Oxlumo®) must advise the approved supplier of the following:
Note: the agency will monitor claims to make sure pharmacies get both payments within their usual timeframes. Escalate any further enquiries via email to PBS Claiming Support. |